VFA
NAVB

Valeo Financial Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Valeo Financial Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-20
Closed – – 1740
2019
Q2 		$0 Buy
+20
New +$39 ﹤0.01% 1720

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Valeo Financial Advisors's NAVB Position: Q3 2019 in Review

Valeo Financial Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2019, closing a stake of 20 shares.

Valeo Financial Advisors first reported a position in NAVB in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 29 funds tracked by Wall St. Rank hold NAVB as of Q3 2019.

  • Valeo Financial Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2019 after selling out during the quarter.
  • Valeo Financial Advisors sold 20 Navidea Biopharmaceuticals Inc. shares in Q3 2019.
  • Valeo Financial Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2019 and held it in 1 quarter.
  • Valeo Financial Advisors's Navidea Biopharmaceuticals Inc. position peaked at $0 in Q2 2019.
  • 29 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2019.

Based on Valeo Financial Advisors's 13F filing for Q3 2019, filed 15 Oct 2019.